Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO Italy 2022 | The growing role of MRD as a clinical endpoint in CLL

Massimo Massaia • 25 Oct 2022
SOHO Italy 2022
Chronic Lymphocytic Leukemia Leukemia

Massimo Massaia, MD, Santa Croce e Carle di Cuneo Hospital, Cuneo, Italy, briefly discusses the growing role of measurable residual disease (MRD) in chronic lymphocytic leukemia (CLL), highlighting its value as a clinical endpoint in patients receiving continuous and fixed-duration treatment. This interview took place at The 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Massimo Massaia

2:01
The role of MRD in CLL patients with high-risk cytogenetics & future perspectives
Massimo Massaia • 25 Oct 2022
1:15
The potential role of MRD in treating CLL patients receiving continuous therapy
Massimo Massaia • 25 Oct 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals